Compare Church & Dwight Co., Inc. (CHD) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Church & Dwight Co., Inc. vs Summit Therapeutics Inc — how do they compare? Church & Dwight Co., Inc. trades at $101.72 (market cap $24.38B), while Summit Therapeutics Inc trades at $15.07 (market cap $12.06B). The key difference: Church & Dwight Co., Inc. is far larger — about 2× Summit Therapeutics Inc's market cap, and Church & Dwight Co., Inc. pays a 1.2% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CHD | SMMT | |
|---|---|---|
Market Cap | $24.38B | $12.06B |
Sector | Consumer Staples | Health |
52-Week High | $105.26 | $26.98 |
52-Week Low | $81.60 | $12.55 |
Enterprise Value | $26.38B | $11.39B |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Church & Dwight (CHD) trades at $101.99, down 1.27% today, with a bullish technical signal and strong fundamentals. Recent Q2 2026 earnings met estimates with 5.8% organic sales growth, and the company raised full-year guidance. Valuation ratios like P/E of 32.94 are elevated, but profitability remains solid with an 11.96% net income margin.
The outlook is positive due to consistent earnings beats and raised guidance, though high valuation and competitive pressures pose risks. Analyst consensus is bullish with a $103.57 price target, supported by institutional holdings and dividend stability.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
